BCTX Valuation

Briacell Therapeutics Corp

Add to Watchlist

Advanced Chart

12.720

+0.095(0.752%)1D

Overview
Forecast
Valuation
Earnings

BCTX Relative Valuation

BCTX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, BCTX is overvalued; if below, it's undervalued.

Historical Valuation

Briacell Therapeutics Corp (BCTX) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -3.31. The fair price of Briacell Therapeutics Corp (BCTX) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：12.72

Fair

-0.55

Trailing

Forward

0.00

EV/EBITDA

Briacell Therapeutics Corp. (BCTX) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.

-0.31

EV/EBIT

Briacell Therapeutics Corp. (BCTX) has a current EV/EBIT of -0.31. The 5-year average EV/EBIT is -1.79. The thresholds are as follows: Strongly Undervalued below -5.49, Undervalued between -5.49 and -3.64, Fairly Valued between 0.07 and -3.64, Overvalued between 0.07 and 1.92, and Strongly Overvalued above 1.92. The current Forward EV/EBIT of -0.31 falls within the Historic Trend Line -Fairly Valued range.

10.56

Briacell Therapeutics Corp. (BCTX) has a current PS of 10.56. The 5-year average PS is 0.32. The thresholds are as follows: Strongly Undervalued below -2.67, Undervalued between -2.67 and -1.18, Fairly Valued between 1.81 and -1.18, Overvalued between 1.81 and 3.30, and Strongly Overvalued above 3.30. The current Forward PS of 10.56 falls within the Strongly Overvalued range.

0.00

P/OCF

Briacell Therapeutics Corp. (BCTX) has a current P/OCF of 0.00. The 5-year average P/OCF is -4.01. The thresholds are as follows: Strongly Undervalued below -16.69, Undervalued between -16.69 and -10.35, Fairly Valued between 2.33 and -10.35, Overvalued between 2.33 and 8.66, and Strongly Overvalued above 8.66. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

-0.87

P/FCF

Briacell Therapeutics Corp. (BCTX) has a current P/FCF of -0.87. The 5-year average P/FCF is -2.03. The thresholds are as follows: Strongly Undervalued below -10.75, Undervalued between -10.75 and -6.39, Fairly Valued between 2.33 and -6.39, Overvalued between 2.33 and 6.70, and Strongly Overvalued above 6.70. The current Forward P/FCF of -0.87 falls within the Historic Trend Line -Fairly Valued range.

Briacell Therapeutics Corp (BCTX) has a current Price-to-Book (P/B) ratio of 0.67. Compared to its 3-year average P/B ratio of -8.30 , the current P/B ratio is approximately -108.10% higher. Relative to its 5-year average P/B ratio of 0.47, the current P/B ratio is about 43.96% higher. Briacell Therapeutics Corp (BCTX) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -86.59%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -57.03% , the current FCF yield is about -100.00% lower.

0.67

P/B

Median3y

-8.30

Median5y

0.47

-110.63

FCF Yield

Median3y

-86.59

Median5y

-57.03

Competitors Valuation Multiple

The average P/S ratio for BCTX's competitors is 0.00, providing a benchmark for relative valuation. Briacell Therapeutics Corp Corp (BCTX) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

BCTX.O

Briacell Therapeutics Corp

Rani Therapeutics Holdings Inc

Performance Decomposition

Market capitalization of BCTX increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of BCTX in the past 1 year is driven by Unknown.